Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  3SBio Inc. (ADR)    YFK

 SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CNY)
Sales 2017 3 600 M
EBIT 2017 1 113 M
Net income 2017 923 M
Debt 2017 1 770 M
Yield 2017 0,43%
Sales 2018 4 445 M
EBIT 2018 1 421 M
Net income 2018 1 189 M
Debt 2018 1 206 M
Yield 2018 0,48%
P/E ratio 2017 23,52
P/E ratio 2018 18,34
EV / Sales2017 6,51x
EV / Sales2018 5,15x
Capitalization 21 667 M
More Financials
Company
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products.It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.The company... 
Sector
Pharmaceuticals
Calendar
08/15Earnings Release
More about the company
Surperformance© ratings of 3SBio Inc. (ADR)
Trading Rating : Investor Rating :
More Ratings
Latest news on 3SBIO INC. (ADR)
02/24 3SBIO : says 3 products listed in 2017 National Drug List
2016 3SBIO : granted exclusive license of diabetes drugs
2016 3SBIO : AstraZeneca Ink Licensing Agreement
2016 3SBIO : gets nod for colorectal cancer drug clinical trial
2016 3SBIO INC. : (01530) says ITP drug get clinical trial approval
2016 3SBIO INC. : (01530) withdraws breast cancer drug application
2016DJChinese Drugmaker Plans up to $3 Billion Hong Kong IPO
2015 3SBIO : Selected as a Constituent of the Hang Seng Composite LargeCap & MidCap I..
2015 3SBIO : Acquires Zhejiang Wansheng Pharmaceutical
2015 3SBIO : Acquires Global Rights to Anti-TNF mAb
More news
Sector news : Biopharmaceuticals
03:42p NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03:14a YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Biopharmaceuticals
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 9,90  CNY
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jing Lou Chairman, President & Chief Executive Officer
Wei hong Xiao Chief Operating Officer
Bo Tan Chief Financial Officer & Executive Director
Zhenping Zhu Chief Scientific Officer, President-R&D
Dong Mei Su Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
3SBIO INC. (ADR)0.00%3 142
BIOGEN INC5.39%59 475
CSL LIMITED21.87%42 756
ALEXION PHARMACEUTICAL..-1.71%27 012
BIOMARIN PHARMACEUTICA..4.83%15 012
GRIFOLS SA14.67%14 629
More Results